Home
On Thursday, 15 January 2026, Chulabhorn Royal Academy, in collaboration with BeiGene (Thailand) Co., Ltd., organized the first workshop of the project “Improving Access to Immunotherapies while Ensuring Sustainability for the Healthcare System” at Phra Mae Thorani Rooms 4–5, 1st Floor, Asawin Grand Convention Hotel. The workshop was presided over by Professor Dr. Ruenpung Sutthen, Acting Deputy Secretary-General of Chulabhorn Royal Academy.
The objective of this workshop was to study and estimate the health and economic outcomes of immunotherapy in the treatment of metastatic lung cancer, as well as to explore approaches to enhancing access to immunotherapies for lung cancer treatment within the context of Thailand. The program featured panel discussions among relevant stakeholders, including representatives from the National Health Security Office, the Social Security Office, the Comptroller General’s Department, the National Cancer Institute, the Department of Medical Services, the Health Intervention and Technology Assessment Program (HITAP), specialist physicians in medical oncology and pulmonology/critical respiratory care, as well as academics and researchers.
The outcomes of the workshop are expected to contribute to the development of action plans and collaborative efforts to effectively improve patient access to lung cancer treatment, ensure the sustainability of healthcare financing policies, align with Thailand’s healthcare context, and ultimately deliver the greatest possible benefit to patients.
